• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Viking Therapeutics Inc.

    4/23/25 5:26:31 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VKTX alert in real time by email
    DEFA14A 1 vktx-2025-04-23-defa14a_.htm DEFA14A DEFA14A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549


    SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.)

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12


    VIKING THERAPEUTICS, INC
    .

    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

    Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     


    img30215864_0.jpg

    Important Notice of Availability of Proxy Materials for the Stockholder Meeting of VIKING THERAPEUTICS, INC. To Be Held On: May 20, 2025 at 8:00 a.m. Pacific Time virtually at https://web.lumiconnect.com/255403211 (password: viking2025) COMPANY NUMBER ACCOUNT NUMBER CONTROL NUMBER This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before 05/06/25. Please visit http://www.astproxyportal.com/ast/20061/, where the following materials are available for view: • Notice of Annual Meeting of Stockholders • Proxy Statement • Form of Electronic Proxy Card • Annual Report on Form 10-K TO REQUEST MATERIAL: TELEPHONE: 888-Proxy-NA (888-776-9962) or 201-299-6210 (for international callers) E-MAIL: [email protected] WEBSITE: https://us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials TO VOTE: ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the meeting date. VIRTUALLY AT THE MEETING: The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet, please visit https://web.lumiconnect.com/255403211 (password: viking2025) and be sure to have your control number available. TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain the toll free number to call. MAIL: You may request a card by following the instructions above. 1. ELECTION OF DIRECTOR NOMINEES FOR CLASS I (term to expire in 2. RATIFICATION OF THE SELECTION OF CBIZ CPAS P.C. AS THE COMPANY'S 2028): INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2025. NOMINEES: Matthew W. Foehr Charles A. Rowland, Jr. 3. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. THE BOARD OF DIRECTORS RECOMMENDS AVOTE "FOR" THE ELECTION OF EACH OF THE DIRECTOR NOMINEES AND "FOR" PROPOSALS 2 AND 3. Please note that you cannot use this notice to vote by mail.


    Get the next $VKTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VKTX

    DatePrice TargetRatingAnalyst
    4/29/2025$104.00Overweight
    Cantor Fitzgerald
    4/8/2025$30.00Neutral
    Goldman
    2/13/2025$102.00Sector Outperform
    Scotiabank
    2/7/2025$38.00Neutral
    Citigroup
    12/2/2024Overweight
    Piper Sandler
    11/22/2024$109.00Buy
    B. Riley Securities
    11/4/2024$90.00 → $102.00Buy
    H.C. Wainwright
    9/11/2024$80.00Overweight
    JP Morgan
    More analyst ratings

    $VKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

    Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 99% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmac

    8/19/25 7:08:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in ObesityPhase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25Continued Progress with Amylin Program; IND Planned 4Q25Strong Quarter-End Cash Position of $808 MillionSAN DIEGO, July 23, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2025, and provided an update on its clinical pipeline and other corporate developm

    7/23/25 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

     Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time           SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2025 after the market close on Wednesday, July 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or

    7/16/25 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Viking Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $104.00

    4/29/25 8:13:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Viking Therapeutics with a new price target

    Goldman initiated coverage of Viking Therapeutics with a rating of Neutral and set a new price target of $30.00

    4/8/25 9:33:02 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Viking Therapeutics with a new price target

    Scotiabank initiated coverage of Viking Therapeutics with a rating of Sector Outperform and set a new price target of $102.00

    2/13/25 8:13:09 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

    4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)

    4/8/25 7:05:30 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    4/2/25 6:29:36 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    SEC Filings

    View All

    Viking Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Viking Therapeutics, Inc. (0001607678) (Filer)

    8/19/25 7:09:43 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.

    SCHEDULE 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    8/6/25 12:19:41 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Viking Therapeutics Inc.

    10-Q - Viking Therapeutics, Inc. (0001607678) (Filer)

    7/23/25 5:01:26 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Zante Greg was granted 7,667 shares and sold $118,428 worth of shares (4,266 units at $27.76), increasing direct ownership by 2% to 168,660 units (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    7/3/25 3:31:07 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Lian Brian was granted 48,333 shares and sold $747,633 worth of shares (26,889 units at $27.80), increasing direct ownership by 0.91% to 2,388,014 units (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    7/3/25 3:31:13 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Mancini Marianna sold $118,473 worth of shares (4,266 units at $27.77) and was granted 7,667 shares, increasing direct ownership by 0.91% to 377,535 units (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    7/3/25 3:30:32 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/12/24 5:54:36 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/4/24 1:54:45 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VKTX
    Financials

    Live finance-specific insights

    View All

    Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

    Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 99% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmac

    8/19/25 7:08:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in ObesityPhase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25Continued Progress with Amylin Program; IND Planned 4Q25Strong Quarter-End Cash Position of $808 MillionSAN DIEGO, July 23, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2025, and provided an update on its clinical pipeline and other corporate developm

    7/23/25 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

     Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time           SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2025 after the market close on Wednesday, July 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or

    7/16/25 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care